Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Geodon
Synonyms :
ziprasidone
Class :
2nd Generation, Antipsychotics
Brand Name :
Geodon
Synonyms :
ziprasidone
Class :
2nd Generation, Antipsychotics
Dosage Forms & Strengths
capsule
80mg
60mg
40mg
20mg
For injection powder
20mg
Initially, 20 mg orally 2 times a day with meals; may be enhanced to every other day when necessary; should not exceed more than 80 mg every 12 hours.
Assess the need for maintaining on a regular basis; clinical research has shown that dosages exceeding 20 mg every 12 hours provide no further benefit.
(associated with acute agitation):
Intramuscular: 10 mg every 2 hours or 20 mg every 4 hours; no more than 40 mg daily; use Intramuscular for up to 3 days, then switch to orally if needed.
Acute treatment: 40 mg orally 2 times a day with meals initially; on day 2, increase to 60-80 mg orally 2 times a day if necessary; modify dose according to tolerability and efficacy within the range of 40-80 mg 2 times a day. Maintenance: Maintain at the same dosage at which the patient was first stabilised; review the necessary for maintenance therapy on a regular basis.
Dose Adjustments
Dosing Modifications Hepatic impairment: Use with caution; the drug is extensively metabolised in the liver, which might increase systemic exposure. Renal impairment: Adjusting the dose is not required with oral administration; caution is necessary with intramuscular administration.
Dosage Forms & Strengths
capsule
80mg
60mg
40mg
20mg
For injection powder
20mg
5 mg daily on days 1 to 3
Titrated to 40 mg daily divided every 12 hours from days 4 to28.
Refer to the adult dosing regimen
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may have an increased QTc-prolonging effect when combined with ziprasidone
It may enhance QTc interval when combined with perphenazine
QTc interval is increased both by lenvatinib and ziprasidone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ziprasidone 
when used together, entrectinib and ziprasidone both increase the QTc interval
when used together, encorafenib and ziprasidone both increase the QTc interval
ziprasidone and gilteritinib, when used in combination, increase the QTc interval
may increase the QTc interval when combined
it increases the toxicity of antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
amisulpiride: they may increase the toxic effect of antipsychotic agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may increase the effect of beta-blockers
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may diminish the serum concentration when combined with ziprasidone
may diminish the serum concentration when combined with ziprasidone
may diminish the serum concentration when combined with ziprasidone
may diminish the serum concentration when combined with ziprasidone
may diminish the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
It may enhance sedation when combined with a shepherd's purse
It may diminish the effects when combined with chasteberry by pharmacodynamic antagonism
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
ziprasidone and mephenesin, when used together, the risk or seriousness of adverse events may rise
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
dihydroergocristine may enhance the vasoconstricting activities of ziprasidone
ziprasidone may increase the antihypertensive activities of muzolimine
the effectiveness of ziprasidone may be decreased when used in combination with ambenonium
when combined with ziprasidone, there may be a decrease in the metabolism of ivacaftor
combining imidazole salicylate with ziprasidone may raise the risk of hypertension
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
nabilone and ziprasidone, when used simultaneously, both increase the sedation
serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the QTc interval
glycopyrrolate inhaled and formoterolÂ
may diminish the effects through pharmacodynamic antagonism
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
eprosartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
valsartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
may decrease the therapeutic effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
it increases the toxicity of antipsychotic agents
may increase the arrhythmogenic effect of Inhalational Anaesthetics
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increasingly adverse effect when combined with amphetamines
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may diminish the absorption when combined
metyrosine: they may increase the toxic effect of antipsychotic agents
may decrease the therapeutic effect of each other when combined
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Could potentially amplify the neurotoxicity of antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
itopride: they may increase the neurotoxic effect of antipsychotic agents
silodosin: they may decrease the therapeutic effect of antipsychotics
pholcodine: they may decrease the therapeutic effect of antipsychotics
may have an increasingly adverse effect when combined with Antipsychotic Agents
the rate of metabolism of tocofersolan may be reduced with ziprasidone
may have an increased neurotoxic effect when combined with antipsychotic agents
the metabolism of asunaprevir can be reduced when combined with ziprasidone
the risk or severity of QTc prolongation can be heightened when prenylamine is combined with ziprasidone
the effectiveness of ziprasidone may be decreased when used in combination with ambenonium
the effects on QT prolongation may be increased
the therapeutic effect of racepinephrine may be reduced
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
nafcillin will decrease the effect of action of ziprasidone by decreasing renal clearance.
The potential for arrhythmogenic effects of mequitazine could be intensified by the presence of antipsychotic agents
Actions and spectrum:
ziprasidone is an atypical antipsychotic drug that works by affecting the levels of certain chemicals, such as dopamine and serotonin, in the brain. It is used to treat schizophrenia and bipolar disorder. ziprasidone has a broad spectrum of activity, meaning it can treat both the positive and negative symptoms of schizophrenia.
Positive symptoms include hallucinations, delusions, and disordered thinking, while negative symptoms include apathy, lack of motivation, and social withdrawal. ziprasidone can also be used to stabilize mood and prevent episodes of mania or depression in patients with bipolar disorder.
Frequency defined
Dizziness (3-16%)
Extrapyramidal symptoms (2-31%)
Nausea (4-12%)
Headache (11%)
Somnolence (11-15%)
Priapism (1%)
Rhinitis (1-4%)
Xerostomia (1-5%)
Dyspepsia (1-8%)
Respiratory disorders (1-8%)
Myalgia (2%)
Anorexia (2%)
Hypoesthesia (2%)
Tachycardia (2%)
Constipation (2-9%)
Cough (3%)
Orthostatic hypotension (5%)
Seizures
Syncope
Frequency not defined
Hyperprolactinemia
Neuroleptic malignant syndrome
Prolonged QT interval
Drug reaction with the eosinophilia
Post marketing reports
Stevens-Johnson syndrome
Black Box Warning:
ziprasidone has a black box warning for an increased risk of death in elderly patients due to dementia-related psychosis. This medication is not approved for treating dementia-related psychosis.
Contraindication/Caution:
Contraindication:
Caution:
Comorbidities:
Pregnancy consideration: US FDA pregnancy category: C
Lactation: It is not known whether ziprasidone is excreted in human milk.Â
Pregnancy category:
Pharmacology:
ziprasidone is a second-generation (atypical) antipsychotic medication. It acts by blocking the action of certain neurotransmitters in the brain, particularly dopamine and serotonin, which are involved in regulating mood, cognition, and behavior.
ziprasidone is a dopamine D2 receptor and serotonin 5-HT2A antagonist and acts as an antagonist at the serotonin 5-HT1A receptor. It has a high affinity for 5-HT2A receptors and moderate to high affinity for dopamine D2 receptors. ziprasidone also has moderate affinity for histamine H1 and alpha-1 adrenergic receptors.Â
Pharmacodynamics:
ziprasidone blocks the serotonin 5-HT2A receptor and dopamine D2 receptor. It also has moderate antagonistic effects on the serotonin 5-HT1A receptor and agonistic effects on the serotonin 5-HT1D receptor.
The blockade of the dopamine D2 receptor results in a reduction of positive symptoms of schizophrenia such as hallucinations, delusions, and disorganized speech. The antagonism of the serotonin 5-HT2A receptor may also contribute to the improvement of negative symptoms of schizophrenia such as lack of motivation, social withdrawal, and blunted affect.
Pharmacokinetics:
Absorption
ziprasidone is rapidly absorbed after oral administration, with peak plasma concentrations reached within 6 hours. The drug has a bioavailability of about 60% due to extensive first-pass metabolism.
Distribution
The drug is highly bound to plasma proteins (>99%) and has a large volume of distribution (1.2 L/kg), indicating that it is extensively distributed throughout the body.
Metabolism
ziprasidone is metabolized primarily by the liver via CYP3A4 and, to a lesser extent, CYP1A2. The major metabolite is benzisothiazolyl piperazine (BITP), which is pharmacologically inactive.
Elimination and excretion
The elimination half-life of ziprasidone is about 10 hours. The drug gets eliminated by hepatic metabolism, with about 20% excreted in the urine and 66% in the feces.
Administration:
ziprasidone is available as an oral capsule and an intramuscular injection. The oral capsule is usually taken twice daily with food. The recommended dose range for adults with schizophrenia is 40-80 mg twice daily, while the recommended dose range for the treatment of bipolar disorder is 40-160 mg twice daily. The intramuscular injection is used for acute agitation in patients with bipolar disorder or schizophrenia.
Patient information leaflet
Generic Name: ziprasidone
Pronounced: [ zi-PRAY-si-done]
Why do we use ziprasidone?
ziprasidone is an antipsychotic medication that is used to treat schizophrenia and bipolar disorder. It works by balancing the levels of certain chemicals in the brain to improve mood, thinking, and behavior. ziprasidone is also sometimes used off-label to treat other conditions such as anxiety and depression.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
